Related Experiment Video
Updated: Jul 2, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Hepatitis C virus infection enhances insulin resistance induced by visceral fat accumulation
Yuichiro Eguchi1, Toshihiko Mizuta, Eriko Ishibashi
1Department of Internal Medicine, Saga Medical School, Saga, Japan. eguchiyu@cc.saga-u.ac.jp
Background/Aims:
To clarify the impact of visceral obesity on hepatitis C virus (HCV)-infected patients, we examined the relationship between insulin resistance development and visceral fat accumulation.
Methods:
We analyzed 87 HCV-infected patients with mild fibrosis (stage 1 or 2) in comparison with 125 sex- and age-matched patients with non-alcoholic fatty liver disease (NAFLD). The degree of visceral fat area (VFA; cm(2)) at the umbilical level was measured by abdominal computed tomography and divided into two grades: no visceral obesity, VFA<100 and visceral obesity, VFA>/=100. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI). Pancreatic beta-cell function was evaluated by homeostasis model assessment of beta-cell function (HOMA-beta). Serum soluble tumour necrosis factor (TNF)-receptors 1 and 2 and adiponectin were measured.
Results:
Insulin resistance evaluated by HOMA-IR and QUICKI was correlated with visceral fat accumulation, and was higher in HCV patients than in NAFLD patients with visceral obesity. HOMA-beta was higher in HCV patients than in NAFLD patients for each VFA grade. Serum-soluble TNF-receptors 1 and 2 were higher in HCV patients than in NAFLD patients with visceral obesity.
Conclusions:
Hepatitis C virus infection is a risk factor for development of insulin resistance, particularly in patients with visceral obesity.
Related Concept Videos
Type II Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
Hepatitis
Chronic Pancreatitis II: Pathophysiology
Cirrhosis II: Pathophysiology
Type I Diabetes II: Pathophysiology
